CTOs on the Move


 
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.janpixbio.com
  • One Broadway, 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.956.2803

Executives

Name Title Contact Details

Funding

Janpix raised $10M on 10/07/2020

Similar Companies

3DBio Therapeutics

3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting​ #3DBio

Appleton Area Health Services

Appleton Area Health Services is a Appleton, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abcuro

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Bellen Health Care System

Bellen Health Care System is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.